Literature DB >> 3176754

Prognosis of intraventricular hemorrhage due to hypertensive hemorrhagic cerebrovascular disease.

M Hayashi1, Y Handa, H Kobayashi, H Kawano, J Nozaki, S Hirose.   

Abstract

The prognosis of intraventricular hemorrhage (IVH) due to hemorrhagic cerebrovascular disease has been regarded as unfavorable. The authors studied factors affecting the prognosis in 55 patients with IVH due to hypertensive thalamic and putaminal hemorrhages. The mortality rate in this study was 38%, a poorer rate than that in patients without IVH (18%). As for morbidity, 50% of the survivors (31% of all patients) with IVH had nor or moderate disability, but the other 50% had severe disability or were in a persistent vegetative state. On the other hand, there was no or moderate disability in 55%, and severe disability or a persistent vegetative state in 27% of the patients without IVH. Patients with intracerebral or intraventricular hematoma volumes greater than 25 ml, Glasgow Coma Scales of less than nine, intracranial pressures above 30 mm Hg, and ventriculocranial ratios over 0.22 had poor prognoses. These results suggest that greater volumes of intracerebral or intraventricular hematoma and the presence of acute hydrocephalus are of great significance when considering the outcomes of IVH cases.

Entities:  

Mesh:

Year:  1988        PMID: 3176754

Source DB:  PubMed          Journal:  Zentralbl Neurochir        ISSN: 0044-4251


  3 in total

Review 1.  Intraventricular fibrinolysis for intracerebral hemorrhage with severe ventricular involvement.

Authors:  Dimitre Staykov; Juergen Bardutzky; Hagen B Huttner; Stefan Schwab
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

2.  Sudden migration of a thalamic hemorrhage into the ventricles.

Authors:  Jae Chan Hwang; Sung Jin Cho; Hyung Ki Park; Jae Chil Chang
Journal:  J Korean Neurosurg Soc       Date:  2010-03-31

3.  Urokinase infusion for severe intraventricular haemorrhage.

Authors:  N G Rainov; W L Burkert
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.